Vaxcyte, Inc. (PCVX)
61.92
-3.76
(-5.72%)
USD |
NASDAQ |
Nov 05, 16:00
61.35
-0.57
(-0.92%)
After-Hours: 20:00
Vaxcyte SG&A Expense (TTM) : 100.22M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 100.22M |
| June 30, 2026 | 132.67M |
| March 31, 2026 | 129.78M |
| December 31, 2025 | 129.37M |
| September 30, 2025 | 125.70M |
| June 30, 2025 | 116.24M |
| March 31, 2025 | 105.68M |
| December 31, 2024 | 92.90M |
| September 30, 2024 | 81.87M |
| June 30, 2024 | 74.49M |
| March 31, 2024 | 67.47M |
| December 31, 2023 | 60.70M |
| September 30, 2023 | 55.12M |
| June 30, 2023 | 50.42M |
| March 31, 2023 | 45.38M |
| December 31, 2022 | 39.81M |
| Date | Value |
|---|---|
| September 30, 2022 | 34.63M |
| June 30, 2022 | 30.26M |
| March 31, 2022 | 26.92M |
| December 31, 2021 | 25.26M |
| September 30, 2021 | 23.28M |
| June 30, 2021 | 21.65M |
| March 31, 2021 | 18.62M |
| December 31, 2020 | 16.02M |
| September 30, 2020 | 13.68M |
| June 30, 2020 | 11.29M |
| March 31, 2020 | 10.51M |
| December 31, 2019 | 8.547M |
| September 30, 2019 | 6.09M |
| June 30, 2019 | 3.58M |
| March 31, 2019 | 1.316M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Moderna, Inc. | 965.00M |
| Vir Biotechnology, Inc. | 77.15M |
| Anavex Life Sciences Corp. | 5.935M |
| Revolution Medicines, Inc. | 278.15M |
| Foghorn Therapeutics, Inc. | 26.38M |